182 related articles for article (PubMed ID: 12915129)
1. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness.
Maggiora P; Lorenzato A; Fracchioli S; Costa B; Castagnaro M; Arisio R; Katsaros D; Massobrio M; Comoglio PM; Flavia Di Renzo M
Exp Cell Res; 2003 Aug; 288(2):382-9. PubMed ID: 12915129
[TBL] [Abstract][Full Text] [Related]
2. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma.
Vanderwerff BR; Church KJ; Kawas LH; Harding JW
Cytokine; 2019 Nov; 123():154762. PubMed ID: 31254927
[TBL] [Abstract][Full Text] [Related]
3. Cross-talk between the proto-oncogenes Met and Ron.
Follenzi A; Bakovic S; Gual P; Stella MC; Longati P; Comoglio PM
Oncogene; 2000 Jun; 19(27):3041-9. PubMed ID: 10871856
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients.
Lee WY; Chen HH; Chow NH; Su WC; Lin PW; Guo HR
Clin Cancer Res; 2005 Mar; 11(6):2222-8. PubMed ID: 15788670
[TBL] [Abstract][Full Text] [Related]
5. Ron kinase transphosphorylation sustains MET oncogene addiction.
Benvenuti S; Lazzari L; Arnesano A; Li Chiavi G; Gentile A; Comoglio PM
Cancer Res; 2011 Mar; 71(5):1945-55. PubMed ID: 21212418
[TBL] [Abstract][Full Text] [Related]
6. Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines.
Chen Q; Seol DW; Carr B; Zarnegar R
Hepatology; 1997 Jul; 26(1):59-66. PubMed ID: 9214452
[TBL] [Abstract][Full Text] [Related]
7. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Catenacci DV; Cervantes G; Yala S; Nelson EA; El-Hashani E; Kanteti R; El Dinali M; Hasina R; Brägelmann J; Seiwert T; Sanicola M; Henderson L; Grushko TA; Olopade O; Karrison T; Bang YJ; Kim WH; Tretiakova M; Vokes E; Frank DA; Kindler HL; Huet H; Salgia R
Cancer Biol Ther; 2011 Jul; 12(1):9-46. PubMed ID: 21543897
[TBL] [Abstract][Full Text] [Related]
8. The MET receptor tyrosine kinase in invasion and metastasis.
Benvenuti S; Comoglio PM
J Cell Physiol; 2007 Nov; 213(2):316-25. PubMed ID: 17607709
[TBL] [Abstract][Full Text] [Related]
9. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family.
Iwama A; Yamaguchi N; Suda T
EMBO J; 1996 Nov; 15(21):5866-75. PubMed ID: 8918464
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte growth factor and macrophage-stimulating protein are upregulated during excisional wound repair in rats.
Cowin AJ; Kallincos N; Hatzirodos N; Robertson JG; Pickering KJ; Couper J; Belford DA
Cell Tissue Res; 2001 Nov; 306(2):239-50. PubMed ID: 11702235
[TBL] [Abstract][Full Text] [Related]
11. MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential.
Williams TA; Longati P; Pugliese L; Gual P; Bardelli A; Michieli P
J Cell Physiol; 1999 Dec; 181(3):507-14. PubMed ID: 10528237
[TBL] [Abstract][Full Text] [Related]
12. Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis.
Peace BE; Hughes MJ; Degen SJ; Waltz SE
Oncogene; 2001 Sep; 20(43):6142-51. PubMed ID: 11593422
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for the binding specificity of human Recepteur d'Origine Nantais (RON) receptor tyrosine kinase to macrophage-stimulating protein.
Chao KL; Gorlatova NV; Eisenstein E; Herzberg O
J Biol Chem; 2014 Oct; 289(43):29948-60. PubMed ID: 25193665
[TBL] [Abstract][Full Text] [Related]
14. The scatter factor signaling pathways as therapeutic associated target in cancer treatment.
Accornero P; Pavone LM; Baratta M
Curr Med Chem; 2010; 17(25):2699-712. PubMed ID: 20586722
[TBL] [Abstract][Full Text] [Related]
15. Macrophage-stimulating protein and its receptor in non-small-cell lung tumors: induction of receptor tyrosine phosphorylation and cell migration.
Willett CG; Wang MH; Emanuel RL; Graham SA; Smith DI; Shridhar V; Sugarbaker DJ; Sunday ME
Am J Respir Cell Mol Biol; 1998 Apr; 18(4):489-96. PubMed ID: 9533936
[TBL] [Abstract][Full Text] [Related]
16. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
Kanteti R; El-Hashani E; Dhanasingh I; Tretiakova M; Husain AN; Sharma S; Sharma J; Vokes EE; Salgia R
BMC Cancer; 2014 Mar; 14():185. PubMed ID: 24628993
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of Ron and Met proto-oncogene expression in epithelial ovarian tumors].
Fracchioli S; Katsaros D; Maggiora P; Di Renzo MF; Massobrio M
Minerva Ginecol; 1999 Oct; 51(10):359-64. PubMed ID: 10638160
[TBL] [Abstract][Full Text] [Related]
18. Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression.
Sugie S; Mukai S; Yamasaki K; Kamibeppu T; Tsukino H; Kamoto T
Hum Cell; 2016 Jan; 29(1):22-9. PubMed ID: 26250899
[TBL] [Abstract][Full Text] [Related]
19. Analogs of the hepatocyte growth factor and macrophage-stimulating protein hinge regions act as Met and Ron dual inhibitors in pancreatic cancer cells.
Church KJ; Vanderwerff BR; Riggers RR; McMicheal MD; Mateo-Victoriano B; Sukumar SR; Harding JW
Anticancer Drugs; 2016 Sep; 27(8):766-79. PubMed ID: 27314431
[TBL] [Abstract][Full Text] [Related]
20. Cross-talk between RON receptor tyrosine kinase and other transmembrane receptors.
Danilkovitch-Miagkova A; Leonard EJ
Histol Histopathol; 2001 Apr; 16(2):623-31. PubMed ID: 11332718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]